Medtronic receives approval for u.s. labeling of the intellis™ platform showing superior back pain relief when using dtm™ spinal cord stimulation

Dublin, march 17, 2021 /prnewswire/ -- medtronic plc (nyse: mdt), the global leader in medical technology, today announced the u.s. food and drug administration (fda) has approved revised commercial labeling for the intellis™ platform with differential target multiplexed (dtm™) programming for the treatment of chronic, intractable back and leg pain. the new labeling will include study outcomes from a multicenter randomized control trial reflecting superior back pain relief with dtm scs when compared to conventional scs.
MDT Ratings Summary
MDT Quant Ranking